Insilico Medicine Completes First-in-Patient Dose for Its Novel QPCTL Inhibitor for Solid tumors in collaboration with Fosun Pharma (IMAGE)

InSilico Medicine

Insilico Medicine Completes First-in-Patient Dose for Its Novel QPCTL Inhibitor for Solid tumors in collaboration with Fosun Pharma

Caption

The drug candidate is co-developed with Fosun Pharma (600196.SH, 02196.HK) for the treatment of advanced malignant tumors.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.